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Abstract
Gene-modified skin grafts, produced through gene transfer to human keratinocyte stem cells, offer the pos-
sibility of therapeutic benefit for inherited skin diseases. We have previously described efficient lentiviral
vector–mediated gene transfer to keratinocyte stem cells and the generation of human skin grafts for the
inherited skin disease, Netherton syndrome, which arises due to mutations in serine protease inhibitor Kazal-type
5 (SPINK5). Vectors incorporating an internal murine retroviral–derived promoter [spleen focus-forming virus
(SFFV)] in combination with a codon-optimized SPINK5 transgene supported high levels of reconstitution and
robust correction of skin architecture. Subsequent longer-term experiments have uncovered unanticipated
silencing phenomena, with loss of SPINK5 gene expression over time. The inadvertent introduction of CpG
sites during codon optimization appears to have rendered vectors susceptible to silencing due to methylation
across the promoter–transgene boundary. Substitution of the methylation-susceptible SFFV promoter with a
572-bp minimal human involucrin promoter (INVOp), which encodes very few CpG sites, prevented re-
pression of the SPINK5 transgene and resulted in durable and highly compartment-specific reconstitution of
lympho-epithelial Kazal-type–related inhibitor (LEKTI) in human skin grafted onto immunodeficient mice. We
conclude that skin grafts modified with lentiviral vectors encoding INVOp offer a suitable platform for
therapeutic gene therapy in Netherton syndrome, and our experience highlights unanticipated effects of
transgene codon optimization.
Introduction
Netherton syndrome (NS) is a life-threatening and de-bilitating inherited skin disorder caused by defective
expression of lympho-epithelial Kazal-type–related inhibitor
(LEKTI), a serine protease inhibitor encoded by the SPINK5
(serine protease inhibitor Kazal-type 5) gene (Chavanas et al.,
2000; Bitoun et al., 2002, 2003). LEKTI is expressed in the
outer compartment of the epidermis and plays a critical role
in the regulation of kallikreins 5 and 7, which hydrolyze the
extracellular corneodesmosomes in the skin (Descargues
et al., 2005, 2006; Ishida-Yamamoto et al., 2005). When control
of kallikreins by LEKTI is lost, hyperactivated kallikreins can
cause premature degradation of corneodesmosomes, re-
sulting in overdesquamation and loss of skin-barrier func-
tion. LEKTI also inhibits elastase 2, an epidermal protease
involved in profilaggrin processing and lipid lamellae
structure formation of the skin, by controlling kallikrein 5–
mediated cleavage of proelastase 2 (Bonnart et al., 2010). In
the absence of curative therapies, we are developing ex vivo
gene-therapy strategies based on lentiviral mediated gene
correction of autologous keratinocyte stem cells for the
generation of graftable bioengineered skin (Di et al., 2011).
We have previously reported that lentiviral mediated gene
expression by a spleen focus-forming virus (SFFV) internal
promoter of codon-optimized SPINK5 (SPINK5co) sup-
ported sufficient LEKTI expression for architectural correc-
tion of NS skin in a skin-humanizedmousemodel. However,
in contrast to normal LEKTI expression, transgene expres-
sion was not compartment-restricted within the epidermis,
but was detectable throughout the basal and suprabasal
layers. Subsequently, longer-term cultures have uncovered
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unanticipated silencing phenomena, which we now dem-
onstrate are associated with methylation of CpG sites within
the distal SFFV enhancer region and spreading across the
transcription start site boundary within the SPINK5co
transgene. We postulate that the process of codon optimi-
zation of the SPINK5 transgene, intended to improve
gene expression, resulted in the inadvertent introduction
of a high number of CpG sites, which then rendered the
SFFV-SPINK5co configuration susceptible to methylation-
mediated silencing. We show that this phenomenon can be
addressed by substitution of SFFV with a 572-bp human
involucrin promoter (INVOp) element (Ghazizadeh et al.,
2002), which has few CpG, mediates highly compartment-
specific SPINK5 expression, and is not prone to repressive
methylation.
Materials and Methods
Vector generation and keratinocyte transduction
SPINK5co was synthesized by GeneArt (Regensburg,
Germany) and was cloned into a previously described
replication-deficient self-inactivating (SIN) HIV-1 lentiviral
vector. The vector encoded the HIV-1 central polypurine
tract (cPPT), start site–mutated woodchuck postregulatory
element (WPRE), and SFFV promoter (Demaison et al., 2002)
(Fig. 1). To generate INVOp-containing vectors, a 572-bp
fragment of involucrin enhancer was cloned from the 2,500-
bp full-length human INVOp (locus AF085346), using the
method described by Ghazizadeh et al. (2002). Two DNA
fragments containing a distal element (–2,473/–2,036) and a
proximal region (–242/–1) of the INVOp were amplified
from genomic DNA by PCR and cloned into pGEM-T vector
(Promega, Southampton, UK). The two amplified fragments
were ligated using restriction sites BglII (–2,102) and MscI
(–194), and the resulting 572-bp INVOp fragment was veri-
fied by sequencing. INVOp was then cloned in place of
SFFV to generate INVOp-SP/GFP and INVOp-GFP. Vector
stocks were pseudotyped with vesicular stomatitis virus
envelope as previously described, concentrated by ultra-
centrifugation, and titered on human 293T cells by flow
cytometry. Keratinocytes were transduced by one round of
exposure to SFFV-GFP, SFFV-SP/GFP, INVOp-GFP, or
INVOp-SP/GFP vectors at a multiplicity of infection of 25.
Flow cytometry analysis
The proportion of green fluorescent protein (GFP)-positive
cells and GFP intensity were monitored by flow cytometry
(Becton Dickinson, San Jose, CA), and data were collected
using CellQuest (Becton Dickinson; V3.0). Values were nor-
malized against initial time points and analyzed by non-
parametric tests using GraphPad Prism 5.
Skin biopsies and keratinocyte cultures
Skin biopsies were obtained by punch biopsy from a pa-
tient with NS (confirmed null homozygous mutations at c.
2200delAA in SPINK5 gene) under a protocol approved by
our Local Ethics Committee and with informed consent from
parents. Primary keratinocytes were isolated from skin bi-
opsies by incubation with 0.25% trypsin-EDTA for 3 hr. Pri-
mary keratinocytes and keratinocyte cell line NTERT cells
(Dickson et al., 2000) were seeded with lethally irradiated 3T3
cells and grown in the keratinocyte culture medium
(Rheinwald, 1989). Transduced and untransduced control
NTERT cells were treated with keratinocyte medium con-
taining 5 lM azacitidine (5’-azacytidine; Pharmion, Hilling-
don, UK), as described previously (Chien et al., 2005), with
medium being replaced every 3 days for up to 40 days.
During the period of 40 days, cells were passaged when they
reaching confluence. Transduced and nontransduced cells
without azacitidine treatment were cultured in parallel.
Pyrosequencing and methylation analysis
DNA methylation analysis was carried out by EpigenDx
(Worcester, MA). In brief, genomic DNA from transduced
cells cultured in the presence or absence of azacitidine was
denatured and treated with sodium bisulfite using the EpiTect
Bisulfite kit (Qiagen, Crawley, UK). Targeted sequences,
which included a 341-bp boundary region of SFFV-SPINK5co
(13 CpGs for SFFV and 8 CpGs for SPINK5co), a 246-bp
boundary region of INVOp-SPINK5co (7 CpGs for INVOp
and 8 CpGs for SPINK5co), a 138-bp boundary region of
SFFV-eGFP (8 CpGs for SFFV and 2 CpGs for eGFP), and a
126-bp boundary region of INVOp-eGFP (3 CpGs for INVOp
and 2 CpGs for eGFP), were amplified from bisulfite-treated
DNA samples using specific forward and biotinylated reverse
primers, followed by pyrosequencing with specific sequencing
FIG. 1. Schematic view of the lentiviral
vector and of the SFFV promoter–transgene
sites susceptible to CpG methylation. The
upper panel shows SIN HIV-1-based viruses,
encoding the SFFV-LTR promoter, the HIV-1
cPPT element, and a mutated WPRE. Fol-
lowing codon optimization, multiple novel
CpG sites were introduced throughout the
SPINK5co transgene compared with the na-
tive SPINK5 gene (MethylPrimer Express
Software v1; Applied Biosystems, Foster
City, CA).
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primers for each amplicon. Quantification of methylation at all
individual CpG sites within the amplified PCR product was
performed using PyroQ-CpG software.
Bioengineered skin preparation and grafting
to immunodeficient mice
The methods for preparing and grafting bioengineered
skin in nude mice have been previously described (Larcher
et al., 2007). In brief, primary NS keratinocytes infected with
lentiviral vectors encoding eGFP or SPINK5-eGFP cDNA
linked to SFFV or INVOp were seeded on top of a fibrin
matrix populated with live primary human fibroblasts
(dermal equivalent). After keratinocytes reached confluence,
the bioengineered skin constructs were grafted onto a dorsum
of 6-week-old female immunodeficient nude mice (NMRI
strain; Elevage-Janvier, Le Genest-St Isle, France). Three mice
were grafted for each condition. Successfully grafted animals
were anesthetized, and the presence of eGFP fluorescent
grafts in the whole animals was monitored using a Kodak
ISO 2000MM live imaging apparatus (Kodak, Rochester, NY)
under appropriate illumination/filter pairs. Close-up photo-
graphs of fluorescent grafted areas were obtained in a
stereomicroscope equipped with a GFP fluorescent illumina-
tion and digital camera (Olympus, Barcelona, Spain). Eight
weeks after grafting, skin samples from grafts were taken post
mortem, embedded in OCT or paraffin, and sectioned for
histological and immunohistochemical examinations.
Immunostaining and immunoblotting
Immunofluorescence staining and histochemistry were
performed on frozen or paraffin tissue sections (6-lm thick-
ness) using methods previously described (Di et al., 2009). A
custom-made affinity-purified rabbit polyclonal antibody
(Eurogentec, Southamton, UK) directed against the C-terminus
of LEKTI was used at 580 ng/ml. For immunoblotting, cells
were lysed in a cooled buffer composed of 50mM Tris-HCl,
pH 8.0, 150mM NaCl, 5mM EDTA, cocktail protease in-
hibitors, 1mM phenylmethanesulfonyl fluoride (PMSF), and
1% Triton X-100 for 15min at 4C. Samples were then
centrifuged at 12,000 rpm for 10min to pellet the insoluble
material. The total protein concentration in the supernatant
was determined using the Bio-Rad protein assay kit (Bio-
Rad, Hertfordshire, UK). Samples from the supernatant
were further diluted in 5· sample buffer containing 100mM
dithiothreitol, 10% sodium SDS, 30% glycerol, 0.001%
bromphenol blue, and 0.5mM Tris-HCl, pH 6.8. Equal quanti-
ties of total protein were loaded in 10% SDS-PAGE. After
electrophoresis, proteins were transferred to polyvinylidene
difluoride membranes and incubated with LEKTI antibody
overnight at room temperature with shaking. On the following
day, membranes were incubated with mouse anti-rabbit IgG
conjugated with horseradish peroxidase secondary antibody
(Sigma, Poole, UK), and signals were detected using the
ECLplus system (GE Healthcare, Buckinghamshire, UK).
Results
Methylation-mediated silencing of SPINK5
gene expression
We previously reported that SIN lentiviral vectors derived
from HIV-1 and incorporating an internal SFFV promoter
upstream of SPINK5co/GFP (SFFV-SP/GFP) mediated high
levels of LEKTI expression in primary keratinocytes, whereas
protein expression from a non–codon-optimized SPINK5
transgene had been barely detectable (Di et al., 2011). We
reasoned that because the native SPINK5 cDNA encodes a
high proportion of rare codons and has a relatively low GC
content, mRNA turnover was likely to be rapid and protein
expression levels may not have been sufficient for thera-
peutic benefit. Therefore, gene optimization was undertaken
using a proprietary algorithm (GeneArt) (Fig. 1). This re-
moved potentially repressive sequences and increased GC
content from 43% in native SPINK5 cDNA to 58% in
SPINK5co. The process also included the replacement of
inhibitory sites (cryptic splice sites, polyA sites, and RNA
instability motifs) and the introduction of a Kozak sequence
to increase translational initiation (Fath et al., 2011). Codon
usage was adapted for expression in human cells, resulting
in a very high ‘‘codon adaptation value’’ (0.93). Thereafter,
vectors encoding SPINK5co mediated LEKTI expression
sufficient to normalize human skin architecture in grafts
derived from patients with NS (Di et al., 2011). However, we
noted a decline in the expression of reporter gene eGFP in
long-term cultured cells with serial propagation, suggesting
repression of transgene expression. To test this, keratinocyte
cell line NTERT cells were transduced with SFFV-SP/GFP
and SFFV-GFP lentiviral vectors, and the intensity of eGFP
expression in these cells was monitored by flow cytometry
over a 40-day period. Interestingly, although eGFP intensity
in cells transduced with the control SFFV-GFP vector did not
change over time (Fig. 2A), it was markedly decreased in
cells transduced with SFFV-SP/GFP vector ( p< 0.01) (Fig.
2B). Western blot analysis of LEKTI expression revealed re-
duction in the expression of LEKTI protein in SFFV-SP/GFP
transduced cells (Fig. 2C). Quantitative PCR for integrated
vector copy number confirmed the presence of stable in-
tegrants, excluding the possibility of vector-mediated toxic-
ity, which may have resulted in the loss of gene-modified
populations (data not shown). As the DNA sequences in
SPINK5co had increased CpG motifs after gene codon opti-
mization compared with those in native SPINK5 (Fig. 1), we
suspected that DNA methylation might be the cause of
SPINK5 transgene silencing. To investigate the possibility of
methylation-mediated silencing, transduced cells were cul-
tured in the presence of the DNA methyltransferase inhibi-
tor, azacitidine. Flow cytometry analysis showed greater
stability of GFP expression for SFFV-SP/GFP transduced
populations (Fig. 2B), and western blot analysis revealed
increased levels of LEKTI expression in cells cultured in the
presence of azacitidine (Fig. 2C). In contrast, there were no
significant changes in SFFV-GFP cells treated with azaciti-
dine (Fig. 2A). These results supported the hypothesis that
methylation-mediated silencing was compromising trans-
gene expression from vectors expressing SP/GFP in combi-
nation with the SFFV promoter.
To investigate this phenomenon further, we quantified the
levels of DNA methylation at individual CpG sites across the
boundary region between the SFFV promoter and SPINK5co,
including the transcription start site. DNA from cells trans-
duced with the SFFV-SP/GFP and cultured in the presence
or absence of azacitidine was extracted after 5, 12, and 40
days and treated with bisulfite before pyrosequencing and
analysis. DNA methylation was quantified, focusing on 13
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CpG sites within 174 bases of distal SFFV promoter and 8
CpG sites within 163 bases of proximal SPINK5 cDNA. The
proportion of methylated CpG sites increased significantly
over time in the absence of azacitidine treatment from
around 6% for both SFFV and SPINK5co regions at day 5 to
15% for SFFV and 19% for SPINK5co at day 40 ( p< 0.001)
(Fig. 3A). Moreover, by day 40, azacitidine treatment re-
sulted in a significant reduction of DNA methylation within
both SFFV and SPINK5co regions (SFFV, 9.1 – 3.6%; SPINK5,
11.2 – 4.1%; p< 0.001) (Fig. 3A). Interestingly, methylation
within the SFFV promoter of control groups transduced with
vectors expressing eGFP alone (SFFV-GFP) was much lower
(4.3– 1.8% at day 40 for SFFV-GFP versus 15.1– 7.0% at day
40 for SFFV-SP/GFP; p< 0.001), with overall levels ranging
from 1.6% to 6.6% (Fig. 3B). Thus, CpG sites within the distal
region of SFFV were more susceptible to methylation when
the promoter was used in combination with codon-optimized,
GC-enriched SPINK5, suggesting spreading of methylation
across the promoter–cDNA boundary.
The human INVOp addresses the silencing
of SPINK5co
Involucrin is an epidermal protein expressed in the supra-
basal layers of stratified squamous epithelium during kera-
tinocyte differentiation. We investigated whether a 572-bp
regulatory element derived from the full-length human
INVOp could mediate SPINK5co transgene expression
and support compartment-specific LEKTI expression. As
INVOp has very few CpG sites (a total of 7 CpGs in INVOp
FIG. 2. SFFV promoter in combination with SPINK5co re-
sults in methylation-mediated DNA silencing. NTERT kerati-
nocytes transduced with lentiviral vectors encoding SFFV-GFP
(A) or SFFV-SP/GFP (B) were cultured in the presence or
absence of 5 lM azacitidine (aza) for a period of 40 days. GFP
intensity in transduced cells cultured over time was moni-
tored by flow cytometry. (A) GFP intensity in cells trans-
duced with SFFV-GFP remained stable, and azacitidine
treatment had no significant effect on these cells. (B) GFP
intensity in cells transduced with SFFV-SP/GFP decreased
over time and was rescued by azacitidine treatment. (C)
LEKTI expression in NTERT cells transduced with SFFV-SP/
GFP detected by western blot decreased over time (lanes 2–5)
and were rescued by azacitidine treatment (lanes 6–9).
FIG. 3. Methylation analysis of the promoter–transgene
boundary in NTERT cells transduced with SFFV-containing
vectors. NTERT keratinocytes transduced with lentiviral
vectors encoding SFFV-GFP or SFFV-SP/GFP were cultured
in the presence or absence of 5lM azacitidine (aza) for a
period of 40 days. DNA was extracted after 5, 12, and 40
days and treated with bisulfite before pyrosequencing and
analysis. (A) Average percentages of methylation within a
341-bp boundary region of SFFV-SPINK5co including 13
CpGs for SFFV (white bars) and 8 CpGs for SPINK5co (black
bars) show increasing methylation over time (*p< 0.001).
Methylation was significantly reduced by day 40, following
azacitidine treatment compared with cells without azacitidine
treatment (**p< 0.001). There was no significant (ns) change
within the azacitidine-treated group over time. (B) Low
methylation levels within a 138-bp boundary region including
8 CpGs for SFFV (white bars) and 2 CpGs for eGFP (black
bars) were detected in cells transduced with SFFV-GFP.
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compared with 26 CpGs within SFFV) (Fig. 4A), we hypoth-
esized that using this promoter might prevent methylation-
mediated silencing of SPINK5co transgene. We incorporated
INVOp into the lentiviral constructs by substituting SFFV to
generate INVOp-SP/GFP and INVOp-GFP vectors. NTERT
keratinocytes were transduced and cultured with or without
azacitidine, for up to 40 days. Flow cytometry analysis
revealed no significant reduction in the proportion of eGFP-
expressing cells or in the intensity of GFP expression in cells
transduced with INVO-SP/GFP over time (Fig. 4B and C). In
addition, western blot analysis showed stable LEKTI expres-
sion over the analyzed period (Fig. 4D).
Next, to analyze the methylation status of INVOp and
SPINK5co, we carried out pyrosequencing and analysis of
bisulfite-treated DNA. DNA from cells transduced with the
INVOp-SP/GFP and INVOp-GFP cultured in the presence or
absence of azacitidine was extracted after 11, 19, and 33 days
in culture and treated with bisulfite before pyrosequencing.
DNA methylation was quantified, focusing on the distal re-
gion of INVOp (7 sites within 106 bp) and the proximal re-
gion of SPINK5co (8 CpG sites within 163 bp). Our results
revealed low levels of methylation within the INVOp region
over time in cells transduced with INVOp-SP/GFP or IN-
VOp-GFP vectors, ranging from around 0% to 2.2% (Fig. 5A
and B). Azacitidine treatment did not change the methylation
status in cells transduced with either vector (Fig. 5A and B).
FIG. 4. INVOp supports stable LEKTI expression. (A)
Schematic view of the INVOp-SPINK5co sites susceptible to
CpG methylation. (B) NTERT cells transduced with INVOp-
SP/GFP were cultured in the presence or absence of 5lM
azacitidine (aza) for a period of 39 days. GFP intensity did
not change in the first 11 days, but was increased following
day 11. This is likely to be a result of enhanced involucrin
expression during keratinocyte differentiation. (C) The pro-
portion of GFP-positive cells remained stable in the presence/
absence of azacitidine treatment. (D) Western blot analysis
with anti-LEKTI antibody shows stable LEKTI expression in
NTERT cells transduced with INVOp-SP/GFP over time.
FIG. 5. Methylation in vectors incorporating the INVOp.
NTERT cells transduced with INVOp-SP/GFP were cultured
in the presence or absence of 5lM azacitidine (aza) for over
30 days. Methylation across the promoter–transgene
boundary was quantified by pyrosequencing following bi-
sulfite treatment of genomic DNA. (A) There was low-level
methylation within the 246-bp boundary region of INVOp-
SPINK5co (white bars, INVOp; black bars, transgene
SPINK5co). (B) The relevant control vector configuration also
showed low-level methylation within a 126-bp boundary
region of INVOp-eGFP (white bars, INVOp; black bars,
eGFP). (C) Methylation at seven individual CpG sites within
the proximal SPINK5co region at the end of the culture pe-
riod was found to be significantly lower in cells transduced
with INVOp-SP vectors (black bars) compared with cells
transduced with SFFV-SP constructs (white bars).
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Importantly, methylation levels within the proximal
SPINK5co were significantly lower than methylation levels
within the same region in vectors incorporating SFFV pro-
moter, reaching 1.5 – 1.0% for INVOp-SP/GFp versus
19.4 – 5.9% for SFFV-SP/GFP ( p< 0.001). This difference was
evident at each individual site analyzed (Fig. 5C). We con-
clude that substitution of INVOp in place of SFFV supports
stable LEKTI expression in vitro and results in reduced sus-
ceptibility to transgene repression.
INVOp supports robust,compartmentalized
LEKTI expression in vivo
To evaluate the efficacy of the INVOp-SP/GFP combina-
tion in a skin-humanized mouse model, we transduced pri-
mary keratinocytes obtained from an NS patient with
INVOp-SP/GFP and INVOp-GFP control vectors. Cells
transduced with SFFV-SP/GFP and SFFV-GFP were included
for comparison. Clonogenicity of keratinocytes transduced
with SFFV-GFP, INVOp-SP/GFP, and INVOp-SP/GFP eval-
uated using colony-forming assay did not reveal significant
differences among cell groups (data not shown). Transduced
cells were expanded and cultured as bioengineered skin
equivalents and grafted onto immunodeficient nude mice as
previously described (Di et al., 2011). NS grafts transduced
with INVOp-GFP showed histological features of NS, in-
cluding psoriasiform changes and hypogranulosis with a
parakeratotic stratum corneum and defective keratinization
(Fig. 6D). LEKTI expression was not detected in grafts trans-
duced with SFFV-GFP or INVO-GFP control vector (Fig. 6F
and H). Although the initial gene-transfer efficiency moni-
tored by flow cytometry for GFP-positive populations was
lower in keratinocytes transduced with INVOp vectors (25%)
compared with SFFV vectors (40%), the level of LEKTI ex-
pression and the extent of architectural correction were
greatest in grafts generated from INVOp-SP/GFP (Fig. 6G
and I). In addition, the localization of suprabasal LEKTI in NS
grafts driven by INVOp closely mirrored the compartmen-
talization of native LEKTI expression (Fig. 6I). Thus, vectors
incorporating INVOp supported durable SPINK5co transgene
expression leading to compartment-specific LEKTI reconsti-
tution and correction of skin architecture.
Discussion
Gammaretroviral vectors, incorporating long terminal re-
peat (LTR) promoters, have been widely used in early-phase
clinical studies (Qasim et al., 2009). The ability of strong
enhancer elements within the LTRs to mediate transactivation
of proto-oncogenes, resulting in insertional mutagenesis, has
been a major concern associated with conventional retroviral
configurations (Hacein-Bey-Abina et al., 2003, 2008; Ott et al.,
2006; Howe et al., 2008) and, more recently, loss of transgene
expression has been documented in clinical studies (Stein
et al., 2010). This has been attributed to various causes, in-
cluding positional variegation effects, promoter methylation,
and histone modification. For example, in a phase 1 study of
retroviral correction of chronic granulomatous disease,
methylation of CpG sites within the SFFV promoter led to
extinction of transgene expression and loss of therapeutic
effects, whereas intact enhancer function mediated clonal
expansion through transactivation effects. Next-generation
SIN vectors, with deleted U3 LTR promoter activity, use
FIG. 6. INVOp supports robust, compartment-specific
LEKTI expression in NS skin grafts. NS keratinocytes were
transduced with INVOp-GFP (D, H) or INVOp-SP/GFP (A-
C, E, I) or SFFV-GFP (F) or SFFV-SP/GFP (G) and grafted
onto nude mice. Skin grafts were examined 8 weeks after
grafting. (A) Macroscopic appearances of the grafts under
transmitted light. (B) Expression of eGFP within the skin
grafts visible under 488-nm (blue) light. (C) Anti-human in-
volucrin antibody staining, revealing the histological de-
marcation of murine (Mo) and human (Hu) skin boundary.
(D, E) Histological appearance of grafts by hematoxylin and
eosin staining. Results showed corrected epidermal struc-
tures with a thinner, well differentiated epidermis in the
INVOp-SP/GFP grafts (E), compared with the control graft
transduced with INVOp-GFP (D), which shows typical fea-
tures of NS with thickened epidermis and incomplete ter-
minal differentiation and hypogranulosis. LEKTI expression
(shown in red) was absent in control groups transduced with
SFFV-GFP (F) or INVOp-GFP (H), but was detectable in
grafts transduced with SFFV-SP/GFP (G) and INVOp-SP/
GFP (I). High-level LEKTI expression with suprabasal com-
partment localization was shown in the INVOp-SP/GFP
graft (I), compared with the SFFV-SP/GFP graft (G) in which
only limited numbers of LEKTI-positive cells were detected.
Scale bar = 50lm for F–I and 200lm for C–E.
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heterologous promoters, which could address concerns relat-
ing to transactivation. However, in many preclinical studies,
internal promoters derived from murine retroviral LTR
sequences have remained popular, as they support high levels
of transcriptional activity in a wide variety of cell types (De-
maison et al., 2002). We have previously described robust and
durable gene expression from SIN HIV-1 vectors incorporat-
ing an internal SFFV-derived promoter in a variety of cell
types, including hematopoietic stem cells, lymphocytes
(Qasim et al., 2007), fibroblasts (Fassone et al., 2010), and
keratinocytes (Di et al., 2011). Evidence is accumulating that,
in susceptible cell lines such as the P19 embryonic carcinoma
line and hematopoietic stem cells, gene expression mediated
by LTR-derived elements is rapidly repressed through CpG
methylation. Notably, the SFFV-LTR includes methylation-
susceptible CpG motifs within its Sp1 transcription binding
site, enhancer core, and CAAT/TATA box elements (Zhang
et al., 2007, 2010).
Several approaches are being investigated to address DNA
methylation and histone modification, which can result in si-
lencing of vector-mediated transgene expression. One strategy
has been to incorporate chromatin insulators such as the
chicken b-globin locus control region HS4 element (cHS4) into
retroviral LTR regions to reduce expression variegation, but
their inclusion may compromise vector titer (Gaszner and
Felsenfeld, 2006), and a recent clinical report has raised ques-
tions about their inclusion in therapeutic vectors (Cavazzana-
Calvo et al., 2010). Alternatively, enhancerless ubiquitous
chromatin opening element (UCOE) sequences, derived from
the human HNRPA2B1-CBX3 locus (A2UCOE), have been
shown to confer stable transgene expression in a variety of
different cell types, including hematopoietic stem cells used for
the correction of murine severe combined immunodeficiency
(Zhang et al., 2007, 2010). UCOEs exhibit a dominant chromatin
opening capability and encode methylation-free CpG islands
that potently resist DNAmethylation. Althoughwe considered
substitution of SFFV with A2UCOE in vectors expressing
SPINK5co, preliminary experiments using previously de-
scribed A2UCOE-GFP lentiviral vectors suggested that these
vectors may not support sufficiently high levels of gene ex-
pression in keratinocytes. Similarly, gene expression derived
from vectors with alternative human promoter elements de-
rived from elongation factor 1-a gene and phosphoglycerate
kinase promoter were notably reduced in comparison with
SFFV (data not shown). In contrast, we found that minimal
(572bp) human INVOp, with low CpG content, mediated
both compartment-specific and repression-resistant transgene
expression.
A general model of epigenetic repression of vector-mediated
gene expression envisages methylation of enhancer-promoter
elements that may spread to nearby CpG sites within the
transgene (Bird and Wolffe, 1999; Curradi et al., 2002). Our
observations are consistent with a model whereby, once
initiated, DNAmethylation is perpetuated in cis and spreads
to neighboring CpG sites, breaching a threshold beyond
which transcription is repressed. We conclude that juxta-
position of the SFFV and SPINK5co resulted in clustering of
methylation-susceptible CpG sites, predisposing to trans-
gene repression over time. Further investigations will be
required to fully elucidate additional mechanisms, such as
chromatin-mediated repression, but we have demonstrated
that substituting of the CpG-rich SFFV promoter with
INVOp circumvents susceptibility to methylation-mediated
silencing of SPINK5co. Deployment of the INVOp is partic-
ularly attractive in the context of inherited skin diseases such
as NS, where gene expression is highly compartmentalized.
In the normal skin, to maintain a constant thickness of epi-
dermis, corneocytes within the uppermost layers of the epi-
dermis are shed by desquamation and are continuously
replaced by keratinocytes undergoing differentiation. Correct
epidermal assembly requires compartmentally restricted gene
expression; for example, both involucrin and LEKTI proteins
are expressed in the uppermost layers of the epidermis. In the
absence of a well-defined promoter associated with the en-
dogenous SPINK5 locus, INVOp provides a valuable alter-
native and supports LEKTI expression in suprabasal layers of
the epidermis. Interestingly, essential proximal regulatory
regions of human INVOp have previously been shown to
encode binding sites for lens epithelium–derived growth
factor (Kubo et al., 2002), a well-defined transcriptional
coactivator and a critical host-cell factor that interacts with
HIV-1 integrase during proviral integration. It is not know
whether this association could influence vector integration
or function, and detailed integration-site characterization
will be required to determine whether the integration profile
of lentiviral vectors encoding INVOp differs from other HIV-
1-derived vectors.
The lentiviral vector system described here has addressed
unanticipated problems associated with our previous proof-
of-principle constructs. Further refinements are under way to
produce a third-generation, four-plasmid, vector system
(Dull et al., 1998) for translational studies and phase I clinical
testing in a clinical trial of gene-modified skin grafts in NS.
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